PROK

In the past six months, ProKidney reported Q1 2026 financial results on May 15, 2026, ending with $224.9 million in cash, expected to fund operations into mid-2027. Kenneth Locke was appointed Chief Technical Officer on June 2, 2026. Q2 2026 financial results on August 10, 2026, showed a loss per share of -$0.15 and revenue of $150K, with $181.6 million in cash, also projected to fund operations into mid-2027. In August 2026, Director Brian J. G. Pereira sold 757,164 shares of Class A Common Stock, and major shareholder Control Empresarial de Capitales S.A. de C.V. converted 63,118,645 Paired Interests into Class A Common Shares. On October 2, 2026, ProKidney announced eight abstracts were selected for presentation at Kidney Week 2026. The stock price has been volatile, experiencing a -9.84% change on September 23, 2026, and a +6.11% change on September 18, 2026, with the price at $1.91 per share as of September 18, 2026, marking a 28.73% decline from the previous year.